UNSPSC 51293004: Benzaprinoxide

This classification denotes an antidepressant agent with the molecular formula C20H20ClNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8J11WBM781, chemically known as 1-propanamine, 3-(1-chloro-5h-dibenzo(a,d)cyclohepten-5-ylidene)-n,n-dimethyl-, n-oxide but generally known as benzaprinoxide, which bears US NIH Compound Identifier 6436093. European Medicines Agency schedules Benzaprinoxide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05739MIG.

UNSPSC 51293004 Benzaprinoxide is a Commodity code that does not reflect the actual work state and local governments are procuring under this designation. The recent opportunities posted under this code involve naloxone procurement, therapeutic pharmacy initiatives, and generic multi-source pharmaceuticals — none of which correspond to benzaprinoxide as a chemical or pharmaceutical product. The mismatch between the code name and recent solicitation content suggests either a tagging error in the source data or that this code is being used as a catch-all for broader pharmaceutical and medical supply categories beyond its nominal scope.

The issuing bodies soliciting under this code span county health departments, state health and human services agencies, and multi-state cooperative purchasing alliances. Seminole County, Florida has posted an IFB for naloxone and drug deactivation systems (due July 26, 2023), the Texas Health and Human Services Commission issued an RFI on Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions (due April 3, 2026), and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026). Activity appears concentrated in Texas, Minnesota, and Florida, with MMCAP's multi-state cooperative structure extending reach to Oregon. The lack of alignment between the code name and actual procurement content makes this code unreliable for business development targeting — the recent opportunities represent pharmaceutical supply and public health initiatives that fall outside benzaprinoxide's typical commodity classification.